Wayne Eskridge published Liver Disease, a free pass on the toboggan ride to hell in Voices - our blog 2022-01-04 15:16:16 -0700
In my last newsletter I commented that I was proud that one of the things we do is help people die. Members who have followed me for a while got it but I made some newer folks uncomfortable so as a way to start the new year I thought a look at real life might be useful.Read more
Wayne Eskridge published Our SUNN Study report has been published in the journal PLOS ONE in Voices - our blog 2021-11-30 14:39:44 -0700
A lot of research is published but not a lot is sponsored by and performed by patients themselves. We are pleased to announce that our SUNN Study (Screening for Undiagnosed NAFLD and NASH) report has been published and the paper is now live on PLOS ONE, an international, peer-reviewed, open-access, online science publication. You can read it by clicking the link below.
Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a population-based risk factor assessment using vibration controlled transient elastography (VCTE)Read more
Wayne Eskridge published The Liver Meeting, A patient's view of the state of the art in Voices - our blog 2021-11-19 11:19:35 -0700
There are two big conferences in the world for people who deal with liver disease. EASL is in Europe in the spring and AASLD is in the US in the fall. This is where the latest research is released, where the cutting edge of knowledge about the disease is shared, and where the future of liver medicine can be glimpsed. It is a time for the superstars of the field to strut their stuff and be recognized by their peers and it is a window into the best of today and a glimpse of what we as patients can look to in the future.
We will follow this note with a more useful review of information we hope will be useful to you as patients, but I wanted to share a general perspective of what I see happening broadly.Read more
Wayne Eskridge published Announcing the NAFLD Screening Fund on NASDAQ in Voices - our blog 2021-10-06 12:40:53 -0600
This is just an update. Almost no one actually watches these little closing bell ceremonies but they are a nice part of our historical record. It was interesting to be mentioned on the big screen on Times Square for a half an hour. Here is a link to the event announcing the NAFLD Screening Fund.Read more
Wayne Eskridge published Announcing the NAFLD Screening Fund in Voices - our blog 2021-10-04 11:44:20 -0600
The Fatty Liver Foundation is launching a public private partnership fund with the long-term goal of screening a million asymptomatic, undiagnosed individuals a year for nonalcoholic fatty liver disease (NAFLD).
NAFLD and its serious advanced version nonalcoholic steatohepatitis (NASH) are epidemic but largely unknown to people. These diseases have subtle symptoms until late stage when they are diagnosed as cirrhosis. Most people know cirrhosis as a disease of alcoholism, and the end result of destruction of the liver is the same, but the cause is different. NAFLD is primarily a disease caused by food. It was unknown before calories became abundant and obesity became common.Read more
Wayne Eskridge published FIRST TIMES -- Do you remember yours? in Voices - our blog 2021-10-01 16:05:56 -0600
A first time is often a turning point, a new direction or a different way. They come in an infinite variety but must flower in their season. Click the First Time button for a 25 second snippet of great wisdom.Read more
Wayne Eskridge published COVID Booster - to jab or not to jab that is the question in Voices - our blog 2021-09-27 13:33:47 -0600
I wrote about the danger of Delta while it was still just a problem for India. Regular readers may recall my comment about it coming to your town. We all know the tune for old folks and those with other illness at this point but it is important to understand that there is more to the story. A booster is now available to some and I see questions about whether it is a good idea to get it. I've had the booster but before I tell you my results lets step back and ask if the risks we face are the same with Delta as they were with our old chum Wuhan. A good measure is dying so a look at some case fatality rates might be fun.Read more
Becky Taub and Paul Friedman, are leading the efforts of Madrigal Pharmaceuticals to develop the first treatment for NAFLD/NASH. That drug is called Resmetirom and is currently in phase 3 trials. Many observers think they will be the first to have a successful drug for fatty liver disease.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is in currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO- NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients.
Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-β and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-β agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly β-selective THR agonist.
Resmetirom has demonstrated the potential for a broad array of therapeutically beneficial effects, not only by improving the non-alcoholic steatohepatitis (NASH) phenotype through reducing liver fat and liver inflammation, and by restoring hepatocytes to normal function, but also by decreasing levels of multiple atherogenic lipids. These pleiotropic actions, coupled with an excellent safety profile, suggest that resmetirom could be the preferred option for treating NASH and for addressing the heightened cardiovascular risk in non-alcoholic fatty liver disease (NAFLD)/NASH patients.
Wayne Eskridge published There is a new ELF in town, sorry no magic this time, but important anyway in Voices - our blog 2021-09-06 20:50:05 -0600
ELF, cute little name but what does it mean to liver patients?
ELF was just approved as a blood test for fibrosis by the FDA and this is an important step in the efforts to develop better tools for diagnosing advanced liver disease and getting away from liver biopsy.
Wayne Eskridge published The CDC talked to me like an adult, sadly I woke up, it was just a dream in Voices - our blog 2021-08-16 16:18:05 -0600
I'm sympathetic to the challenge the CDC faces but I hate the way they dumb down their messages about this virus. By talking to us like we are 6th graders they just add to the confusion. There are things you need to understand about this virus so that you can respond appropriately. See the summary notes below.Read more
Wayne Eskridge published Survey says...liver patients need to be identified to be more aware of their risks in Voices - our blog 2021-08-13 11:42:55 -0600
Recently, we sent out a survey to our community to get an idea about COVID-19 vaccines and their impact among immunocompromised people with liver disease. We knew we were posing this survey to our community, which is likely more informed and focused on fatty liver disease, so these results should be considered in that context. Though we did not achieve statistical significance with any of our findings, thanks to you, we got over 100 responses and found some interesting, yet not completely surprising, insights. Click on the image below to see the top line results from the survey.
Wayne Eskridge published Virus mutation factories, how might you become one of them? in Voices - our blog 2021-08-10 08:44:06 -0600
Twenty million people with the liver disease NASH, or non-alcoholic steatohepatitis, are also more likely than the average person to be infected with the COVID Delta variant and suffer from long COVID. Many of these chronically ill will become variant factories increasing the risk of developing new and deadlier strains. We’re working hard to prevent that, aren't we?Read more
Wayne Eskridge published Medical care, I don't know whether I'm mad or sad, It is worse than I feared in Voices - our blog 2021-07-27 13:35:00 -0600
I really want to be mad at someone, but who?
You are here because you have an interest in health. Suppose you had a dangerous condition that takes a decade or two to develop but had no symptoms. Would it matter to you if no one told you?
Buzz off you say??? Life is like that you say, lots of things happen to people. There's nobody to blame. It's in the fine print on the back of the ticket. Life isn't fair and no one gets out alive. Don't waste the energy thinking it can be better?Read more
Wayne Eskridge published COVID mutations, vaccines, chronic disease -- things you need to know in Voices - our blog 2021-05-10 14:19:44 -0600
Infection rates and vaccine failures - some points to ponder
We have been seeing the headlines about the COVID tragedy in India as hospitals turn patients away and the nation runs out of oxygen as people are literally dying in line waiting to refill oxygen tanks. India faces a historic crisis and you probably imagine the densely packed cities and poverty are the cause. But wait, what about the REST OF THE STORY?
If you or someone you care about has a chronic disease, there are things about the story of India that will likely affect you in coming months. I've written about COVID variants before, click here for a review. The UK strain has become the dominant variant in the US and it has done that because it is about 50% more infectious than the Wuhan original. The University of British Columbia recently released an actual image of the UK variant spike protein which helps us understand that. The image is an amazing science story about how they could take this picture but a story for another time.
Contact for help accessing patient support and cost reduction programs.
Scott Ritchey is an account executive who works with Xifaxan and patients suffering from HE. I have discussed the problem that many patients have with insurance coverage and drug costs and he has volunteered to help people connect to the proper resources for free or reduced cost medication. Here is his contact information. If you contact him you can tell him that I referred you to him if you wish.
Scott D. Ritchey
Regional Account Executive – Mid Atlantic
Wayne Eskridge published I can see clearly now, the patient journey through liver land in Voices - our blog 2021-04-21 06:58:55 -0600
In the doctor/patient relationship there is a physician process which is called the "intention to diagnose". That may seem odd, but diagnosis requires a deliberate action by the doctor. You may be more familiar with the idea of the "intention to treat". You may have heard the argument that there is no value in identifying a condition if it can't be fixed and in that case there is no intention to treat so no intention to diagnose.
As a liver disease patient you may have learned about your condition when you were fairly advanced. Why does that happen? Is it a lack of the intention to diagnose, a failure of diagnosis, inadequate tools or training, or is something else happening? We are hosting a webinar on Wednesday the 17th at 12:00 Eastern. We will be discussing non-invasive testing with a couple of experts, Dr Mona Munteanu and Dr Stephen Harrison, and we will talk about the diagnosis problem and the several tools available for detection and monitoringRead more
Fatty Liver Foundation organizer
As a liver disease patient my goal is to help others understand, manage, or prevent the disease